Congenital myasthenic syndrome

Validating the use of digital health technologies to monitor disease symptoms in infants, children and adults with congenital myasthenic syndrome.

Congenital Myasthenic Syndrome (CMS) is a group of inherited disorders characterized by variable degrees of generalized fixed and fatigable muscle weakness, difficulty swallowing and speaking, and ptosis. The severity and specific symptoms can vary depending on the exact genetic mutation involved. There is no cure for CMS.

Our research in CMS, in close collaboration with the National Institute of Neurological Disorders and Stroke, is focused on developing and validating digital health technologies for tracking disease symptoms in infants, children and adults with CMS.

Our clinical studies in CMS

BioDigit CMS

Status: Not yet recruiting
Number of participants: 75
Monitoring period: Up to 5 years
Study product: LEGSys, PAMSys, PAMSys ULM, BioDigit Speech, BioDigit Video

Our research partner

If you're interested in discussing our research, including access to our study protocol and data, or using our products in your clinical trials and research, please contact us.

Request Demo